Traditional Herbal Medicine Candidates as Complementary Treatments for COVID‐19: A Review of Their Mechanisms, Pros and Cons
Open accessThe DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Abstract
Coronavirus disease 2019 (COVID‐19) is a new infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) that belongs to the coronavirus family. The first case was reported in December 2019, and the disease has become a pandemic. Impaired immune regulation is one of the factors that play a role in its pathogenesis and results in poor outcomes of COVID‐19 patients. There have been many studies with drug candidates used as antivirals or immunomodulators. However, the results of these investigations showed that the drug candidates were not significantly effective against the disease. Meanwhile, people believe that consuming herbal immunomodulators can prevent or even cure COVID‐19. Unfortunately, specific preclinical and clinical trials to evaluate the effects of herbal immunoregulators have not been conducted. Certain natural compounds might be effective for the treatment of COVID‐19 based on general concepts from previous experiments. This review discusses some herbal agents extracted from various plants, including Echinacea, Cinchona, Curcuma longa, and Curcuma xanthorrhiza, which are considered for the treatment of COVID‐19. In addition, we discuss the pros and cons of utilising herbal medicine during the COVID‐19 pandemic, draw some conclusions, and make recommendations at the end of the session.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Gautret, P., Lagier, J.-C., Parola, P., Hoang, V. T., Meddeb, L., Mailhe, M., Doudier, B., Courjon, J., Giordanengo, V., Vieira, V. E., et al. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.105949 · Cited by 5,288 · cited 2×
“From this evidence, quinine as a chloroquine analogue might be predicted to have beneficial effects in eliminating the COVID-19 [28].”
BackgroundRetractedClinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884
COVID-19: consider cytokine storm syndromes and immunosuppression
Mehta, P., McAuley, D. F., Brown, M., Sanchez, E., Tattersall, R. S., & Manson, J. J. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30628-0 · Cited by 9,664 · cited 3×
“In COVID-19, this cytokine storm is characterised by the increase of interleukin (IL)-2, IL-7, granulocyte-colony stimulating factor, IFN-c, inducible protein (IP)-10, monocyte chemoattractant protein (MCP)-1, macrophage inflammatory protein (MIP) 1-α, and tumour necrosis factor (TNF)-α [17].”
Wang, M., Cao, R., Zhang, L., Yang, X., Liu, J., Xu, M., Shi, Z., Hu, Z., Zhong, W., & Xiao, G. (2020) · Cell Research · doi:10.1038/s41422-020-0282-0 · Cited by 6,958 · cited 3×
“+is mechanism results in the inhibition of viral infection in vitro [20].”
BackgroundInfluentialA Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
Cao, B., Wang, Y., Wen, D., Liu, W., Wang, J., Fan, G., Ruan, L., Song, B., Cai, Y., Wei, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001282 · Cited by 5,187 · cited 1×
“+ese studies also suggested using lopinavir/ritonavir associated with some adverse events, mainly in the gastrointestinal tract [26, 27].”
BackgroundWan, Y., Shang, J., Graham, R., Baric, R. S., & Li, F. (2020) · Journal of Virology · doi:10.1128/jvi.00127-20 · Cited by 4,341 · cited 4×
“respiratory tract, known as the angiotensin-converting enzyme-2 (ACE2) receptor [6].”
BackgroundInfluentialCoronaviruses: An Overview of Their Replication and Pathogenesis
Fehr, A. R., & Perlman, S. (2015) · Methods in Molecular Biology · doi:10.1007/978-1-4939-2438-7_1 · Cited by 3,787 · cited 7×
“+e other is to expose the fusion peptide or cleave at S2 [12].”
BackgroundInfluentialWang, Y., Zhang, D., Du, G., Du, R., Zhao, J., Jin, Y., Fu, S., Gao, L., Cheng, Z., Lu, Q., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31022-9 · Cited by 3,440
Robbins and Cotran Pathologic Basis of Disease
Hoda, S. A., & Hoda, R. S. (2020) · American Journal of Clinical Pathology · doi:10.1093/ajcp/aqaa163 · Cited by 3,365
Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?
Fang, L., Karakiulakis, G., & Roth, M. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30116-8 · Cited by 2,911 · cited 2×
“Curcumin activates the same mechanism when it is administered as an ACE inhibitor [42, 44, 45].”
Background
Cited by
Traditional Chinese medicine in COVID-19
Lyu, M., Fan, G., Xiao, G., Wang, T., Xu, D., Gao, J., Ge, S., Li, Q., Ma, Y., Zhang, H., et al. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.09.008 · Cited by 224
Metadata
- Authors
- Nugraha, R. V., Ridwansyah, H., Ghozali, M., Khairani, A. F., & Atik, N.
- Venue
- Evidence-Based Complementary and Alternative Medicine
- Publisher
- Wiley
- Published
- 2020-01
- Volume
- 2020
- Issue
- 1
- Pages
- 2560645-2560645
- ISSN
- 1741-427X (ISSN-L)
- 1741-4288
- OpenAlex
- W3092490057
- Cited by
- 233
- References
- 62
- FWCI
- 26.55
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.